查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561471

2024-2032 年按产品类型、给药途径、疾病、应用和地区分類的疫苗佐剂市场报告

Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2023年全球疫苗佐剂市场IMARC Group达9.965亿美元。由于传染病发病率上升、免疫学和疫苗技术的重大里程碑、对罕见疾病的认识不断提高、未建成人口对大流行疫苗接种工作的兴趣增加、政府支出迅速增长以及需求增加，全球疫苗佐剂市场正在快速成长。

疫苗佐剂市场分析：

  • 主要市场驱动因素：基于多种因素，疫苗佐剂市场前景正在扩大，例如全球范围内越来越重视个人化医疗，根据每个人独特的免疫需求调整疫苗配方，推动疫苗佐剂市场扩大的很大一部分份额。此外，生物资讯学和系统生物学的新技术使人们对免疫反应有了更深入的了解，并随后改进了佐剂设计，大大满足了疫苗佐剂市场的需求。除此之外，随着癌症和阿兹海默症等慢性疾病治疗性疫苗的大量涌入，为扩大佐剂的应用开闢了一条重要途径，再加上抗生素抗药性的增加，需要开发更强大的疫苗，这进一步推动了佐剂的发展。众多的环境变化和不断上升的病原体威胁也导致了动态变化，促进了对佐剂不断创新的需求。
  • 主要市场趋势：疫苗佐剂市场的主要趋势包括转向合成和分子确定的佐剂，作为增强佐剂安全性和有效性的手段。影响疫苗佐剂市场份额的另一个因素是向可以刺激体液和细胞免疫的佐剂系统发展，这种方法认识到此类条件和治疗的多种复杂性，并转化为先进的疫苗佐剂市场预测。人们对黏膜疫苗的兴趣也在增长，因为这些疫苗透过针对感染源位点提供更全面的保护。可持续且经济可行的生产是另一个趋势，这是疫苗佐剂市场未来的关键组成部分。
  • 地理趋势：目前，疫苗佐剂市场概况的全球领导者是北美，其凭藉强大的医疗基础设施和研发（R＆D）资金，使其成为全球领先者。此外，在大型製药公司的存在和领先研究机构的创新的支持下，公众的高度认识提高了疫苗佐剂的市场价格。因此，大多数疫苗佐剂市场统计数据体现在安全性的提高、功效的提高和成本的降低。由于医疗保健支出不断增加以及人们对疫苗可预防疾病的认识不断增加，欧洲和亚太地区潜力最大。
  • 竞争格局：疫苗佐剂产业的一些主要市场参与者包括 Adjuvatis、Agenus Inc.、Croda International Plc、CSL Limited、Dynavax Technologies、InvivoGen、Novavax Inc.、OZ Biosciences、Phibro Animal Health Corporation、SEPPIC、SPI Pharma、 ETC 。
  • 挑战与机会：疫苗佐剂市场最重大的挑战是与广泛的临床试验和测试相关的监管和安全问题，以证明佐剂的功效和可能的健康风险。然而，展望未来，这在不同方面都是一个机会。 COVID-19大流行增加了疫苗佐剂市场的投资。因此，疫苗佐剂市场分析持续成长，探索新型佐剂以彻底改变疫苗设计，提升全球健康安全性。

疫苗佐剂市场趋势：

疫苗和免疫学技术的进步

免疫学在疫苗佐剂的开发方面取得了重大进展，新佐剂比以前想像的更有效、更安全。技术进步使得能够设计出能够选择性增强对抗原的免疫反应的佐剂，从而显着提高疫苗对抗世界各地多种病原体的能力。最近，2024 年 2 月，艾伯维 (AbbVie) 和 Tentarix Biotherapeutics 宣布建立多年战略合作伙伴关係，共同开发肿瘤学和免疫学领域的生物候选药物。该协议价值超过6400万美元。候选药物的开发将结合艾伯维在肿瘤学和免疫学方面的能力与 Tentarix 的专有 Tentacles 平台，以发现和开发针对每个医学分支中的一个靶标的有条件活性的多特异性生物製剂。这将激活可以调节疾病途径的免疫细胞，同时减少通常与非特异性治疗相关的安全问题。

对罕见疾病的认识与理解不断提高

对罕见疾病的日益认识加速了疫苗开发的独特挑战。这种新的认识激起了人们对可以根据不同利益相关者的具体需求进行客製化的疫苗佐剂的兴趣。至于欧盟，他们将 RD 定义为欧洲人口中每 10 万人中受影响人数少于 50 人。然而，美国门诊孤儿药法案将 RD 定义为影响美国不到 20 万人。其他定义包括刚果每 10 万人中低至 5 人，而印度最高为每 10 万人中 76 人。平均而言，全球每 10 万人中就有 40 人受到 RD 影响。最近，根据 3,585 个 RD，罕见病患病率占世界人口的 3.5% 至 5.9%，相当于 263 至 4.46 亿人。

全球推动疫苗接种以应对流行病威胁

以新冠肺炎 (COVID-19) 为代表的对抗流行病威胁的斗争引发了一场史无前例的全球疫苗接种运动，推动疫苗佐剂市场成为优先公共卫生问题的焦点。此外，疫苗佐剂的主要用途是增强免疫反应、疫苗稳定性、提高疫苗效率和减少疫苗剂量，进而推动市场成长。 「根据ABC 新闻报道，每週新增15,141 例因COVID-19 入院的病例。根据美国疾病控制与预防中心(CDC) 的信息，这与2024 年4 月初的情况大致相同。但并不像以前那么高。根据美国疾病管制与预防中心 (CDC) 通报，在新冠病毒大流行期间，总共有超过 600 万美国人住院治疗。

疫苗佐剂市场区隔：

IMARC Group提供了每个细分市场的主要趋势的分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品类型、给药途径、疾病和应用对市场进行了分类。

按产品类型划分：

  • 佐剂乳剂
  • 病原体成分
  • 颗粒佐剂
  • 组合佐剂
  • 其他的

助剂乳液占据大部分市场份额

该报告根据产品类型对市场进行了详细的细分和分析。这包括佐剂乳液、病原体成分、颗粒佐剂、组合佐剂等。根据该报告，佐剂乳液代表了最大的部分。

佐剂乳剂细分市场的推动因素是对具有增强功效和更持久免疫力的疫苗的需求不断增长。这种兴趣源于乳剂佐剂能够激发强烈而广泛的免疫反应，使其成为流感和 COVID-19 等复杂疾病的疫苗的理想选择。乳剂佐剂的多功能性与多种抗原相容，进一步增强了它们的吸引力。此外，奈米技术的进步改进了这些佐剂的递送机制，提高了它们的有效性，同时保持了安全性。旨在优化乳剂配方的持续研究和开发工作对于满足不断增长的疫苗佐剂市场需求至关重要，强调了它们在未来疫苗开发策略中的关键作用。

依给药途径分类：

  • 口服
  • 肌肉注射
  • 鼻内
  • 皮下
  • 皮内
  • 其他的

肌肉注射代表领先的细分市场

该报告根据给药途径对市场进行了详细的细分和分析。这包括口服、肌肉内、鼻内、皮下、皮内等。根据该报告，肌肉注射占最大部分。

肌肉注射细分市场的推动因素是对需要深入组织渗透才能获得最佳功效的疫苗的需求不断增长，例如针对流感、破伤风和 COVID-19 的疫苗。这种方法之所以受到青睐，是因为它能够将大量疫苗直接输送到血液供应丰富的肌肉中，促进更强、更快的免疫反应。此外，与其他方法相比，肌肉注射途径因其给药相对方便、不适感最小且不良反应风险较低而受到青睐，使其成为全球疫苗接种计划中广泛接受的做法。疫苗吸收率的一致性和支持其有效性的广泛历史资料进一步促进了其采用，突显了该领域的成长。

依疾病分类：

  • 癌症
  • 传染病
  • 其他的

传染病占大部分市场份额

该报告根据疾病提供了详细的市场细分和分析。这包括癌症、传染病等。报告称，传染病占最大部分。

传染病领域是由全球流行病日益流行和新出现的传染病威胁所推动的，这凸显了对有效疫苗的迫切需求。国际旅行、都市化和气候变迁等因素导致传染病的传播，因此需要快速开发和部署含有强效佐剂的疫苗。政府和国际对抗传染病的倡议以及对研发的大量投资进一步推动了该领域的成长。此外，公众意识和医疗基础设施的改善在支持疫苗接种计划方面发挥着重要作用，从而增加了对有效对抗这些疾病的创新疫苗佐剂的需求。

按应用划分：

  • 研究
  • 商业的

研究代表了领先的细分市场

该报告根据应用程式提供了详细的市场细分和分析。这包括研究和商业。根据该报告，研究代表了最大的部分。

疫苗佐剂市场的研究领域受到对针对更广泛病原体（包括新出现和重新出现的传染病）的更有效疫苗的需求不断增长的推动。这种需求加上对免疫系统复杂性的日益了解，促使科学家探索能够引发更强、更持久免疫反应的新型佐剂配方。此外，针对个人基因组成的个人化医疗和疫苗的推动推动了对创新佐剂的探索。生物技术和奈米技术的进步进一步推动了这一领域的发展，使得能够开发出可以精确设计的下一代佐剂，以提高疫苗的有效性，同时最大限度地减少副作用。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美市场领先，占据最大的疫苗佐剂市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是疫苗佐剂最大的区域市场。

由于对疫苗研发（R＆D）的大量投资，北美的疫苗佐剂预计将主导市场，这些疫苗旨在解决各种传染病以及公共和私营部门日益增长的健康问题。该地区具有疫苗审批流程快速的优势，这鼓励製药公司扩大和增加对辅助技术的投资。此外，北美拥有许多顶尖研究中心的优势，与生物技术领域的合作频繁。因此，它是医疗技术和创新领域。此外，为了提高疫苗的有效性，佐剂的使用越来越多地认识到提高疫苗的有效性和安全性的重要性，从而推动了北美市场的扩张。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

  • 疫苗佐剂市场的主要参与者正在积极参与研发活动，以推出创新且更有效的佐剂配方。这些努力旨在增强疫苗引起的免疫反应，确保针对各种传染病以及癌症等慢性病的治疗性疫苗提供更广泛和更持久的保护。例如，2022 年 2 月，Novavax Inc. 宣布了其 3 期临床试验的积极中期结果，该试验评估了其 COVID-19 候选疫苗 NVX-CoV2373 与其专有佐剂 Matrix-M 的结合。结果显示对 COVID-19 具有很强的功效，整体疗效超过 90%。合作和伙伴关係是一项共同策略，共同学术机构、研究组织和生物技术公司的专业知识，加速下一代佐剂的开发。此外，这些公司正在投资先进技术并探索新型佐剂物质，包括合成分子和天然化合物，以提高疫苗功效和安全性。随着公司在复杂的环境中将其创新推向市场，监管合规性和追求快速审批流程也至关重要。透过这些行动，主要参与者为全球疫苗佐剂市场的动态成长和发展做出了重大贡献。

疫苗佐剂市场新闻：

  • 2022 年 9 月：Dynavax Technologies 开始了一项重大努力，开始对其 COVID-19 候选疫苗 DVX-COV2373 进行 2 期临床试验。该疫苗采用该公司专有的佐剂 CpG 1018 配製而成，为持​​续对抗 COVID-19 大流行提供了一条有希望的途径。该试验的独特之处在于其与流行病防范创新联盟（CEPI）的合作，该联盟是一个全球合作伙伴关係，专注于加速针对新出现传染病的疫苗的开发。这项 2 期试验的主要目标是扩展早期发现并评估 DVX-COV2373 在更大人群中的安全性和有效性。这一步骤对于确保疫苗符合严格的监管标准，同时衡量其在不同人群中的表现至关重要。
  • 2024 年2 月：CSL（ASX：CSL；USOTC：CSLLY）发表了AEGIS-II 3 期试验的主要结果，该试验评估了CSL112（载脂蛋白AI [人类]）与安慰剂相比在降低重大疾病风险方面的有效性与安全性。

本报告回答的关键问题

  • 2023年全球疫苗佐剂市场规模是多少
  • 2024-2032年全球疫苗佐剂市场预计成长率是多少
  • 推动全球疫苗佐剂市场的关键因素是什么
  • COVID-19对全球疫苗佐剂市场有何影响
  • 根据产品类型，全球疫苗佐剂市场的细分如何
  • 根据给药途径，全球疫苗佐剂市场的细分如何
  • 全球疫苗佐剂市场按疾病划分是怎样的
  • 基于应用的全球疫苗佐剂市场区隔是怎样的
  • 全球疫苗佐剂市场的重点区域有哪些
  • 10. 全球疫苗佐剂市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2023年全球疫苗佐剂市场规模有多大？ 2024-2032年全球疫苗佐剂市场的预期成长率是多少？
  • 推动全球疫苗佐剂市场的关键因素是什么？
  • COVID-19对全球疫苗佐剂市场有何影响？
  • 根据产品类型，全球疫苗佐剂市场的细分如何？
  • 根据给药途径，全球疫苗佐剂市场的细分如何？
  • 根据疾病的不同，全球疫苗佐剂市场的细分如何？
  • 根据应用，全球疫苗佐剂市场的细分如何？
  • 全球疫苗佐剂市场的重点区域有哪些？
  • 全球疫苗佐剂市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球疫苗佐剂市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品类型

  • 佐剂乳剂
    • 市场趋势
    • 市场预测
  • 病原体成分
    • 市场趋势
    • 市场预测
  • 颗粒佐剂
    • 市场趋势
    • 市场预测
  • 组合佐剂
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依管理途径

  • 口服
    • 市场趋势
    • 市场预测
  • 肌肉注射
    • 市场趋势
    • 市场预测
  • 鼻内
    • 市场趋势
    • 市场预测
  • 皮下
    • 市场趋势
    • 市场预测
  • 皮内
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依疾病分类

  • 癌症
    • 市场趋势
    • 市场预测
  • 传染病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按应用

  • 研究
    • 市场趋势
    • 市场预测
  • 商业的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adjuvatis
    • Agenus Inc.
    • Croda International Plc
    • CSL Limited
    • Dynavax Technologies
    • InvivoGen
    • Novavax Inc.
    • OZ Biosciences
    • Phibro Animal Health Corporation
    • SEPPIC
    • SPI Pharma
Product Code: SR112024A4385

The global vaccine adjuvants market size reached US$ 996.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,639.3 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Analysis:

  • Major Market Drivers: The vaccine adjuvants market outlook is expanding based on various factors, such as growing emphasis on personalized medicine taking place globally adjusts vaccine formulations to the unique immunological needs of each individual, driving a large share of the vaccine adjuvants market expansion. Moreover, novel technologies in bioinformatics and systems biology have led to a deeper understanding of immune responses and subsequent refinement in adjuvant design, contributing considerably to the vaccine adjuvants market demand. Apart from this, with the influx of therapeutic vaccines for chronic diseases such as cancer and Alzheimer's, a significant avenue has been opened to expand the adjuvant's application, supplemented by the rise in antibiotic resistance that demands the development of more robust vaccines, which is further propelling the vaccine adjuvants market growth. There have also been numerous environmental changes and rising pathogen threats that contribute to dynamic changes, promoting the need for constant adjuvant innovation.
  • Key Market Trends: The key vaccine adjuvants market trends include to shift to synthetic and molecularly defined adjuvants as a means of enhancing the safety and efficacy profile of adjuvants. Another factor contributing to the vaccine adjuvants market share is the move towards adjuvant systems that can stimulate both humoral and cellular immunity as an approach that recognizes the multiple levels of complexity in such conditions and treatments and translates into an advanced vaccine adjuvants market forecast. The interest in mucosal vaccines has also grown, as these vaccines offer more comprehensive protection by targeting the origin site of infection. Sustainable and economically feasible production is another trend, which is a critical component for the future of vaccine adjuvants market.
  • Geographical Trends: Currently, the global leader in vaccine adjuvants market overview is North America based on robust healthcare infrastructure and research and development (R&D) funding, making it a global leader. Moreover, high public awareness has increased the vaccine adjuvants market price supported by presence of large pharmaceuticals and innovation from leading research institutes. Hence, the most vaccine adjuvants market statistics are expressed in the improved safety profiles, efficacy improvements, and cost reductions. European and Asia-Pacific regions hold the highest potential due to rising healthcare spending and awareness of vaccine-preventable diseases.
  • Competitive Landscape: Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.
  • Challenges and Opportunities: The most significant challenge in the vaccine adjuvants market is the regulatory and safety issues associated with extensive clinical trial and testing to prove the adjuvants' efficacy and possible health risks. However, promising the future, it's an opportunity in different aspects. The COVID-19 pandemic has surged the investments in the vaccine adjuvants market. As a result, the vaccine adjuvants market analysis continues to grow, exploring novel adjuvants to revolutionize vaccine design densifies the global health safety.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie , and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, route of administration, diseases, and application.

Breakup by Product Type:

  • Adjuvant Emulsions
  • Pathogen Components
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

Adjuvant Emulsions accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others. According to the report, adjuvant emulsions represented the largest segment.

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

  • Oral
  • Intramuscular
  • Intranasal
  • Subcutaneous
  • Intradermal
  • Others

Intramuscular represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, intramuscular, intranasal, subcutaneous, intradermal, and others. According to the report, intramuscular represented the largest segment.

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

  • Cancer
  • Infectious Diseases
  • Others

Infectious diseases accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes cancer, infectious diseases, and others. According to the report, infectious diseases represented the largest segment.

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

  • Research
  • Commercial

Research represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes research and commercial. According to the report, research represented the largest segment.

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Vaccine Adjuvants Market News:

  • In September 2022: Dynavax Technologies embarked on a significant endeavor by commencing a Phase 2 clinical trial for their COVID-19 vaccine candidate, DVX-COV2373. This vaccine, formulated with the company's proprietary adjuvant CpG 1018, represents a promising avenue in the ongoing fight against the COVID-19 pandemic. What distinguishes this trial is its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership focused on accelerating the development of vaccines against emerging infectious diseases. The primary objective of this Phase 2 trial is to expand upon earlier findings and evaluate DVX-COV2373's safety and efficacy in a larger population. This step is crucial in ensuring that the vaccine meets stringent regulatory standards while also gauging its performance across diverse demographics.
  • In February 2024: CSL (ASX:CSL; USOTC:CSLLY) announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).

Key Questions Answered in This Report

  • 1. What was the size of the global vaccine adjuvants market in 2023?
  • 2. What is the expected growth rate of the global vaccine adjuvants market during 2024-2032?
  • 3. What are the key factors driving the global vaccine adjuvants market?
  • 4. What has been the impact of COVID-19 on the global vaccine adjuvants market?
  • 5. What is the breakup of the global vaccine adjuvants market based on the product type?
  • 6. What is the breakup of the global vaccine adjuvants market based on route of administration?
  • 7. What is the breakup of the global vaccine adjuvants market based on the diseases?
  • 8. What is the breakup of the global vaccine adjuvants market based on the application?
  • 9. What are the key regions in the global vaccine adjuvants market?
  • 10. Who are the key players/companies in the global vaccine adjuvants market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Adjuvant Emulsions
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pathogen Components
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Particulate Adjuvants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Adjuvants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intramuscular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intranasal
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Subcutaneous
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intradermal
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Diseases

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Research
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Commercial
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Adjuvatis
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agenus Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Croda International Plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Dynavax Technologies
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 InvivoGen
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novavax Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 OZ Biosciences
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Phibro Animal Health Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 SEPPIC
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 SPI Pharma
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Vaccine Adjuvants Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Vaccine Adjuvants Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Vaccine Adjuvants Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Vaccine Adjuvants Market: Breakup by Diseases (in %), 2023
  • Figure 7: Global: Vaccine Adjuvants Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Vaccine Adjuvants Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Vaccine Adjuvants (Pathogen Components) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Vaccine Adjuvants (Pathogen Components) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Vaccine Adjuvants (Particulate Adjuvants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Vaccine Adjuvants (Particulate Adjuvants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Vaccine Adjuvants (Combination Adjuvants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Vaccine Adjuvants (Combination Adjuvants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Vaccine Adjuvants (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Vaccine Adjuvants (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Vaccine Adjuvants (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Vaccine Adjuvants (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Vaccine Adjuvants (Intramuscular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Vaccine Adjuvants (Intramuscular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Vaccine Adjuvants (Intranasal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Vaccine Adjuvants (Intranasal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Vaccine Adjuvants (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Vaccine Adjuvants (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Vaccine Adjuvants (Intradermal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Vaccine Adjuvants (Intradermal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Vaccine Adjuvants (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Vaccine Adjuvants (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Vaccine Adjuvants (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Vaccine Adjuvants (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Vaccine Adjuvants (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Vaccine Adjuvants (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Vaccine Adjuvants (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Vaccine Adjuvants (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Vaccine Adjuvants (Research) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Vaccine Adjuvants (Research) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Vaccine Adjuvants (Commercial) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Vaccine Adjuvants (Commercial) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia-Pacific: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia-Pacific: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Vaccine Adjuvants Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Vaccine Adjuvants Industry: SWOT Analysis
  • Figure 91: Global: Vaccine Adjuvants Industry: Value Chain Analysis
  • Figure 92: Global: Vaccine Adjuvants Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Adjuvants Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Vaccine Adjuvants Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Vaccine Adjuvants Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Vaccine Adjuvants Market Forecast: Breakup by Diseases (in Million US$), 2024-2032
  • Table 5: Global: Vaccine Adjuvants Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Vaccine Adjuvants Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Vaccine Adjuvants Market: Competitive Structure
  • Table 8: Global: Vaccine Adjuvants Market: Key Players